PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
23.04%
R&D growth above 10% signals aggressive investment. Seth Klarman would demand evidence of future payoff potential.
21.61%
G&A growth above 5% signals concerning overhead expansion. Seth Klarman would demand justification for increased costs.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.65%
Operating expenses growth above 10% signals concerning cost expansion. Seth Klarman would demand justification.
22.65%
Total costs growth above 5% signals concerning expansion. Seth Klarman would demand justification.
No Data
No Data available this quarter, please select a different quarter.
3.49%
D&A growth 0-5% reflects moderate asset expansion. Benjamin Graham would check if growth drives future value.
-23.08%
Negative EBITDA growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-22.65%
Negative operating income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-58.12%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
-23.20%
Negative pre-tax income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.20%
Negative net income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-16.67%
Negative EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
-22.50%
Negative diluted EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
5.52%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
0.56%
Diluted share increase 0-2% indicates slight dilution. Howard Marks would investigate necessity.